A phase II clinical study evaluated the efficacy and safety of the MEK inhibitor trametinib (2 mg QD) combined with a low dose of dabrafenib (50 mg BID) in previously treated melanoma patients harboring NRAS Q61R/K/L mutations. Preliminary data showed manageable skin toxicity and clinically meaningful disease control. According to MyCancerGenome, Binimetinib has demonstrated clinical efficacy in NRAS-mutant melanomas containing the Q61K subtype. Additionally, several phase I/II trials include Q61K as one of the enrollment genotypes, providing a foundation for precision-matched therapeutic strategies.
NRAS (Neuroblastoma RAS viral oncogene homolog) belongs to the RAS family of GTPases and plays a key role in cell proliferation, differentiation, and survival signaling. The Q61K mutation is commonly observed in various solid tumors, particularly melanomas, and leads to sustained activation of signal transduction pathways that are difficult to counteract with conventional EGFR/BRAF inhibitors.
Our A375-NRAS-Q61K-KI cell line, created via homology arm–mediated precise gene knock-in, retains the original background of A375 cells while faithfully reproducing the in vivo tumor biology driven by NRAS Q61K.
Biological Functions of NRAS
Sustained Activation of the MAPK/ERK Pathway Following NRAS Q61K knock-in, A375 cells exhibit high levels of ERK phosphorylation even in the absence of exogenous growth factors, validating the functional integrity of the model.
Enhanced Proliferation and Migration Capacity In vitro CCK-8 and wound healing assays showed that knock-in cells exhibited an approximately 1.8-fold increase in proliferation rate and nearly double the migration distance, mimicking a highly invasive tumor phenotype.
The NRAS Q61K mutation acts as a driver event in multiple cancers, including melanoma, pancreatic cancer, and medulloblastoma, and is frequently associated with drug resistance. The A375-NRAS-Q61K-KI cell line enables in-depth exploration of:
- Altered sensitivity of mutant NRAS to targeted agents (MEK inhibitors, ERK inhibitors);
- Combination therapy strategies to overcome monotherapy resistance;
- The mechanistic role of new targets (e.g., SOS1, SHOC2) in NRAS-driven tumors.
Current Landscape of Melanoma Research
Globally, NRAS-mutant models are mainly based on mouse xenografts and chemically induced cell lines, while precise knock-in (KI) models remain rare. The establishment of our A375-NRAS-Q61K-KI cell line not only fills the gap in human-derived in vitro models but also provides:
- A reproducible and stable cellular platform for high-throughput drug screening;
- A precise validation tool for researchers studying signaling network mechanisms;
- A preclinical resource for evaluating drug tolerance and toxicity.
With its precision, stability, and high phenotypic fidelity, the A375-NRAS-Q61K-KI cell line is poised to become a powerful tool for NRAS-driven tumor research and new drug development. Kyinno Biotechnology sincerely invites research institutions and pharmaceutical companies to collaborate in accelerating innovation in targeted cancer therapies.
Products and Services
A375-NRAS-Q61K-KI Cell Line In Vitro Validation Data
A375 Cell Line In Vivo Validation Data
References:
- Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable Ras: Mission possible? Nat Rev Drug Discov. 2014 Nov;13(11):828–851.
- Xu Z, Li H, Chen S, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024; (in press).
- Smith J, Patel R, Nguyen L. KRAS inhibitors: resistance drivers and combinatorial strategies. Semin Cancer Biol. 2024;89:102–115.
